{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:41:11Z","timestamp":1792269671341,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009397","name":"Medizinischen Fakult\u00e4t, Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","award":["2723- 0-0"],"award-info":[{"award-number":["2723- 0-0"]}],"id":[{"id":"10.13039\/501100009397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Preserflo MicroShunt is a novel microinvasive bleb forming device for the treatment of primary open-angle glaucoma. The intermediate- and long-term success and the impact of this procedure on corneal endothelial cell density remain to be investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this prospective observational study, 62 eyes of 55 glaucoma patients (mean age\u2009\u00b1\u2009SD: 67.0\u2009\u00b1\u200915.0\u00a0years) receiving a Preserflo MicroShunt were included. Corneal endothelial cell density, intraocular pressure and best corrected visual acuity were assessed preoperatively and at 3, 6, 9, 12, 18 and 24\u00a0months postoperatively. Success rates, bleb revision rates and complications were analysed. Complete success was defined as an intraocular pressure reduction of\u2009\u2265\u200920% and achieving a target pressure of\u2009\u2264\u200918,\u2009\u2264\u200915 or\u2009\u2264\u200912\u00a0mmHg without antiglaucoma medication. Qualified success indicated that the criteria were reached with or without medication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Corneal endothelial cells showed no significant decline over 24\u00a0months (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Intraocular pressure showed a substantial reduction postoperatively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), decreasing from 29.6\u2009\u00b1\u20098,3\u00a0mmHg to 13.0\u2009\u00b1\u20094.3\u00a0mmHg after 24\u00a0months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Complete and qualified success with a target pressure\u2009\u2264\u200915\u00a0mmHg was achieved in 52.9% and 54.6% of cases after 24\u00a0months, respectively. Best corrected visual acuity did not change after 24\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Preserflo MicroShunt had no negative side effects on corneal endothelial cells and showed favourable success rates after 2\u00a0years in patients with open-angle glaucoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-024-06508-8","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T10:01:42Z","timestamp":1716285702000},"page":"3661-3670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Intermediate-term impact on corneal endothelial cells and efficacy of Preserflo MicroShunt implantation in patients with open-angle glaucoma \u2013 a prospective study over two years"],"prefix":"10.1007","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-7883","authenticated-orcid":false,"given":"Caroline J.","family":"Gassel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Nasyrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogomil","family":"Voykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"6508_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1874364100903020038","volume":"3","author":"AL Coleman","year":"2009","unstructured":"Coleman AL, Kodjebacheva G (2009) Risk factors for glaucoma needing more attention. Open ophthalmol J 3:38\u201342. https:\/\/doi.org\/10.2174\/1874364100903020038","journal-title":"Open ophthalmol J"},{"key":"6508_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ophtha.2019.10.002","volume":"127","author":"SJ Gedde","year":"2020","unstructured":"Gedde SJ, Feuer WJ, Lim KS, Barton K, Goyal S, Ahmed II, Brandt JD, Group PTVTS (2020) Treatment outcomes in the primary tube versus trabeculectomy study after 3 years of follow-up. Ophthalmology 127:333\u2013345","journal-title":"Ophthalmology"},{"key":"6508_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ajo.2019.07.015","volume":"208","author":"G Reiss","year":"2019","unstructured":"Reiss G, Clifford B, Vold S, He J, Hamilton C, Dickerson J, Lane S (2019) Safety and effectiveness of CyPass supraciliary micro-stent in primary open-angle glaucoma: 5-year results from the COMPASS XT study. Am J Ophthalmol 208:219\u2013225. https:\/\/doi.org\/10.1016\/j.ajo.2019.07.015","journal-title":"Am J Ophthalmol"},{"key":"6508_CR4","doi-asserted-by":"publisher","unstructured":"Gambini G, Carl\u00e0 MM, Giannuzzi F, Caporossi T, De Vico U, Savastano A, Baldascino A, Rizzo C, Kilian R, Caporossi A, Rizzo S (2022) PreserFlo(\u00ae) MicroShunt: an overview of this minimally invasive device for open-angle glaucoma. Vision (Basel) 6. https:\/\/doi.org\/10.3390\/vision6010012","DOI":"10.3390\/vision6010012"},{"key":"6508_CR5","doi-asserted-by":"publisher","first-page":"101238","DOI":"10.1016\/j.ajoc.2021.101238","volume":"25","author":"C Chamard","year":"2022","unstructured":"Chamard C, Hammoud S, Bluwol E, Lachkar Y (2022) Endothelial cell loss 5 years after Preserflo MicroShunt implantation: about two cases. Am J Ophthalmol Case Rep 25:101238","journal-title":"Am J Ophthalmol Case Rep"},{"key":"6508_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jbm.b.33525","volume":"105","author":"L Pinchuk","year":"2017","unstructured":"Pinchuk L, Riss I, Batlle JF, Kato YP, Martin JB, Arrieta E, Palmberg P, Parrish RK, Weber BA, Kwon Y (2017) The development of a micro-shunt made from poly (styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater 105:211\u2013221","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"6508_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/ijg.0000000000002052","volume":"31","author":"M IbarzBarber\u00e1","year":"2022","unstructured":"IbarzBarber\u00e1 M, Mart\u00ednez-Gald\u00f3n F, Caballero-Magro E, Rodr\u00edguez-Pi\u00f1ero M, Ta\u00f1\u00e1-Rivero P (2022) Efficacy and safety of the Preserflo Microshunt with mitomycin c for the treatment of open angle glaucoma. J Glaucoma 31:557\u2013566. https:\/\/doi.org\/10.1097\/ijg.0000000000002052","journal-title":"J Glaucoma"},{"key":"6508_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ogla.2021.08.005","volume":"5","author":"AM Fea","year":"2022","unstructured":"Fea AM, Laffi GL, Martini E, Economou MA, Caselgrandi P, Sacchi M, Au L (2022) Effectiveness of MicroShunt in patients with primary open-angle and pseudoexfoliative glaucoma: a retrospective European multicenter study. Ophthalmol Glaucoma 5:210\u2013218. https:\/\/doi.org\/10.1016\/j.ogla.2021.08.005","journal-title":"Ophthalmol Glaucoma"},{"key":"6508_CR9","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1097\/IJG.0000000000000368","volume":"25","author":"JF Batlle","year":"2016","unstructured":"Batlle JF, Fantes F, Riss I, Pinchuk L, Alburquerque R, Kato YP, Arrieta E, Peralta AC, Palmberg P, Parrish RK (2016) Three-year follow-up of a novel aqueous humor microshunt. J Glaucoma 25:e58\u2013e65","journal-title":"J Glaucoma"},{"key":"6508_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ajo.2019.07.016","volume":"208","author":"JH Lass","year":"2019","unstructured":"Lass JH, Benetz BA, He J, Hamilton C, Von Tress M, Dickerson J, Lane S (2019) corneal endothelial cell loss and morphometric changes 5 years after phacoemulsification with or without CyPass micro-stent. Am J Ophthalmol 208:211\u2013218. https:\/\/doi.org\/10.1016\/j.ajo.2019.07.016","journal-title":"Am J Ophthalmol"},{"key":"6508_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ajo.2009.04.016","volume":"148","author":"E-K Lee","year":"2009","unstructured":"Lee E-K, Yun Y-J, Lee J-E, Yim J-H, Kim C-S (2009) Changes in corneal endothelial cells after Ahmed glaucoma valve implantation: 2-year follow-up. Am J Ophthalmol 148:361\u2013367","journal-title":"Am J Ophthalmol"},{"key":"6508_CR12","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ajo.2012.09.001","volume":"155","author":"V KalininaAyuso","year":"2013","unstructured":"KalininaAyuso V, Scheerlinck LM, de Boer JH (2013) The effect of an Ahmed glaucoma valve implant on corneal endothelial cell density in children with glaucoma secondary to uveitis. Am J Ophthalmol 155:530\u2013535. https:\/\/doi.org\/10.1016\/j.ajo.2012.09.001","journal-title":"Am J Ophthalmol"},{"key":"6508_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40123-021-00428-0","volume":"11","author":"M Ibarz-Barber\u00e1","year":"2022","unstructured":"Ibarz-Barber\u00e1 M, Morales-Fern\u00e1ndez L, Corroto-Cuadrado A, Martinez-Gald\u00f3n F, Ta\u00f1\u00e1-Rivero P, G\u00f3mez de Lia\u00f1o R, Teus MA (2022) Corneal endothelial cell loss after PRESERFLO\u2122 MicroShunt implantation in the anterior chamber: anterior segment OCT tube location as a risk factor. Ophthalmol Ther 11:293\u2013310. https:\/\/doi.org\/10.1007\/s40123-021-00428-0","journal-title":"Ophthalmol Ther"},{"key":"6508_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2020.06.050","volume":"128","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Liu Y, Thanapaisal S, Oatts J, Luo Y, Ying GS, Wang J, McLeod SD, Gedde SJ, Han Y (2021) The effect of tube location on corneal endothelial cells in patients with ahmed glaucoma valve. Ophthalmology 128:218\u2013226. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.050","journal-title":"Ophthalmology"},{"key":"6508_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/aos.13161","volume":"95","author":"AN Tan","year":"2017","unstructured":"Tan AN, Webers CA, Berendschot TT, de Brabander J, de Witte PM, Nuijts RM, Schouten JS, Beckers HJ (2017) Corneal endothelial cell loss after Baerveldt glaucoma drainage device implantation in the anterior chamber. Acta Ophthalmol 95:91\u201396. https:\/\/doi.org\/10.1111\/aos.13161","journal-title":"Acta Ophthalmol"},{"key":"6508_CR16","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.ophtha.2021.05.023","volume":"128","author":"ND Baker","year":"2021","unstructured":"Baker ND, Barnebey HS, Moster MR, Stiles MC, Vold SD, Khatana AK, Flowers BE, Grover DS, Strouthidis NG, Panarelli JF (2021) Ab-Externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology 128:1710\u20131721. https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.023","journal-title":"Ophthalmology"},{"key":"6508_CR17","doi-asserted-by":"publisher","first-page":"251584142211256","DOI":"10.1177\/25158414221125697","volume":"14","author":"U Qidwai","year":"2022","unstructured":"Qidwai U, Jones L, Ratnarajan G (2022) A comparison of iStent combined with phacoemulsification and endocyclophotocoagulation (ICE2) with the PreserFlo MicroShunt and XEN-45 implants. Ther Adv Ophthalmol 14:25158414221125696. https:\/\/doi.org\/10.1177\/25158414221125697","journal-title":"Ther Adv Ophthalmol"},{"key":"6508_CR18","doi-asserted-by":"publisher","unstructured":"Jamke M, Herber R, Haase MA, Jasper CS, Pillunat LE, Pillunat KR (2023) PRESERFLO \u2122 MicroShunt versus trabeculectomy: 1-year results on efficacy and safety. Graefes Arch Clin Exp Ophthalmol: 1\u201315. https:\/\/doi.org\/10.1007\/s00417-023-06075-4","DOI":"10.1007\/s00417-023-06075-4"},{"key":"6508_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/ijg.0000000000002325","volume":"32","author":"F Anton Steindor","year":"2023","unstructured":"Anton Steindor F, Trigaux C, Holtmann C, Spaniol K, Geerling G, Borrelli M (2023) Preserflo MicroShunt: efficacy and endothelial cell density. J Glaucoma 32:1018\u20131021. https:\/\/doi.org\/10.1097\/ijg.0000000000002325","journal-title":"J Glaucoma"},{"key":"6508_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ogla.2022.11.006","volume":"6","author":"L Van Lancker","year":"2023","unstructured":"Van Lancker L, Saravanan A, Abu-Bakra M, Reid K, Quijano C, Goyal S, Rodrigues I, Lascaratos G, Trikha S, Barwood C, Combe E, Kulkarni A, Lim KS, Low S (2023) Clinical outcomes and cost analysis of PreserFlo versus trabeculectomy for glaucoma management in the United Kingdom. Ophthalmol Glaucoma 6:342\u2013357. https:\/\/doi.org\/10.1016\/j.ogla.2022.11.006","journal-title":"Ophthalmol Glaucoma"},{"key":"6508_CR21","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1111\/aos.14968","volume":"100","author":"KR Pillunat","year":"2022","unstructured":"Pillunat KR, Herber R, Haase MA, Jamke M, Jasper CS, Pillunat LE (2022) PRESERFLO\u2122 MicroShunt versus trabeculectomy: first results on efficacy and safety. Acta Ophthalmol 100:e779\u2013e790. https:\/\/doi.org\/10.1111\/aos.14968","journal-title":"Acta Ophthalmol"},{"key":"6508_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/tvst.10.13.26","volume":"10","author":"M IbarzBarber\u00e1","year":"2021","unstructured":"IbarzBarber\u00e1 M, Hern\u00e1ndez-Verdejo JL, Bragard J, Burguete J, Fern\u00e1ndez LM, Rivero PT, de Lia\u00f1o RG, Teus MA (2021) Evaluation of the ultrastructural and in vitro flow properties of the PRESERFLO MicroShunt. Transl Vis Sci Technol 10:26. https:\/\/doi.org\/10.1167\/tvst.10.13.26","journal-title":"Transl Vis Sci Technol"},{"key":"6508_CR23","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41433-022-01995-7","volume":"37","author":"R Bhayani","year":"2023","unstructured":"Bhayani R, Mart\u00ednez de la Casa JM, Figus M, Klabe K, Rabiolo A, Mercieca K (2023) Short-term safety and efficacy of Preserflo\u2122 Microshunt in glaucoma patients: a multicentre retrospective cohort study. Eye 37:644\u2013649","journal-title":"Eye"},{"key":"6508_CR24","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1007\/s12325-021-01811-w","volume":"38","author":"L Quaranta","year":"2021","unstructured":"Quaranta L, Micheletti E, Carassa R, Bruttini C, Fausto R, Katsanos A, Riva I (2021) Efficacy and safety of PreserFlo\u00ae MicroShunt after a failed trabeculectomy in eyes with primary open-angle glaucoma: a retrospective study. Adv Ther 38:4403\u20134412","journal-title":"Adv Ther"},{"key":"6508_CR25","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/j.ophtha.2013.07.049","volume":"120","author":"JF Kirwan","year":"2013","unstructured":"Kirwan JF, Lockwood AJ, Shah P, Macleod A, Broadway DC, King AJ, McNaught AI, Agrawal P (2013) Trabeculectomy in the 21st century: a multicenter analysis. Ophthalmology 120:2532\u20132539. https:\/\/doi.org\/10.1016\/j.ophtha.2013.07.049","journal-title":"Ophthalmology"},{"key":"6508_CR26","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1001\/archophthalmol.2011.182","volume":"129","author":"BA Francis","year":"2011","unstructured":"Francis BA, Hong B, Winarko J, Kawji S, Dustin L, Chopra V (2011) Vision loss and recovery after trabeculectomy: risk and associated risk factors. Arch Ophthalmol 129:1011\u20131017","journal-title":"Arch Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06508-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06508-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06508-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T01:02:50Z","timestamp":1732323770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06508-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["6508"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06508-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"13 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study adhered to the principles of the Declaration of Helsinki of 1964. Prior to surgery, all patients provided informed consent, along with additional written consent for study participation. Ethical approval was granted by the local institutional ethics committee of the University of T\u00fcbingen (project number: 037\/2021BO2).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CG, DW, EN and TS certify that they have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript. BV has received speaker honoraria and advisory board compensation fees from AbbVie Deutschland GmbH, Novartis and Santen GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}